Stock Research: SCI Pharmtech

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

SCI Pharmtech

TAI:4119 TW0004119003
51
  • Value
    60
  • Growth
    82
  • Safety
    Safety
    58
  • Combined
    84
  • Sentiment
    22
  • 360° View
    360° View
    51
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

SCI Pharmtech, Inc. is a Taiwan-based company focused on manufacturing and selling Active Pharmaceutical Ingredients (APIs). The company operates in the pharmaceutical industry, producing APIs, API intermediates, and special chemicals. It distributes its products in Taiwan, Europe, the Americas, and other parts of Asia. In the last fiscal year, the company had a market cap of $254 million, profits of $13 million, and revenue of $46 million. The number of employees is not available.

more
Index
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
60 22 16 35
Growth
82 74 97 83
Safety
Safety
58 27 51 88
Sentiment
22 8 20 37
360° View
360° View
51 7 36 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
14 12 25 28
Opinions Change
50 50 50 50
Pro Holdings
n/a 32 38 55
Market Pulse
1 1 1 n/a
Sentiment
22 8 20 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
60 22 16 35
Growth
82 74 97 83
Safety Safety
58 27 51 88
Combined
84 27 56 86
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
25 18 9 20
Price vs. Earnings (P/E)
25 14 42 20
Price vs. Book (P/B)
64 31 29 48
Dividend Yield
89 44 21 75
Value
60 22 16 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
87 94 49 83
Profit Growth
90 70 100 23
Capital Growth
81 18 95 84
Stock Returns
7 56 71 65
Growth
82 74 97 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
60 41 55 96
Refinancing
19 24 21 35
Liquidity
75 49 78 100
Safety Safety
58 27 51 88

Similar Stocks

Discover high‑ranked alternatives to SCI Pharmtech and broaden your portfolio horizons.

CTBC Financial Holding

TAI:2891
Country: Taiwan
Industry: Diversified Banks
Size: Medium
Full Stock Analysis

Galaxy Entertainment

HKG:27
Country: Hong Kong
Industry: Casinos & Gaming
Size: X-Large
Full Stock Analysis

Subaru

TYO:7270
Country: Japan
Industry: Automobile Manufacturers
Size: X-Large
Full Stock Analysis

Wistron

TAI:3231
Country: Taiwan
Industry: Technology Hardware & Peripherals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The only positive is high growth. The stock is expensive (low Value Rank), risky to finance, and carries critical professional sentiment. This is a risky proposition. Avoid unless you have exceptional conviction that the growth alone will overcome the price and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: